South Africa concludes the sale of their Oxford-AstraZeneca vaccines to the African Union after the country stopped using these vaccines because they were found to be not highly effective against the 501.V2 variant.
South Africa concludes the sale of the Oxford-AstraZeneca vaccine to the African Union after the country halted its use after it was found to be not effective against 501.V2 variant.
South Africa concludes the sale of their Oxford-AstraZeneca vaccines to the African Union after the country stopped usingthesevaccinesbecause they were found to be not highlyeffective againstthe 501.V2 variant.